Repare Therapeutics said Tuesday it has appointed Steve Forte as executive vice president and chief financial officer. The company, which has offices in Cambridge, MA and Montreal is developing immune-oncology drugs by leveraging a concept known as synthetic lethality. In 2017 it emerged from stealth with $68 million in outside financing to advance its efforts; in September it raised $82.5 million more.
Most recently Forte was CFO of Clementia Pharmaceuticals, which was acquired by French pharmaceutical company Ispen for $1.3 billion earlier this year. His previous experience includes nearly a decade at Aptalis Pharma, which was later acquired by Forest Labs (now part of Allergan (NYSE: AGN)). Forte succeeds Katina Dorton, who joined Repare as CFO in May and has since left “to pursue other interests,” according to the company.